New FDA Draft Guidance Regarding Financial Disclosures by Clinical Investigators Print
Written by   
Wednesday, 03 August 2011 13:21

New recommendations recently released by the FDA demonstrate the changing environment for conflicts of interest management and emphasize the need for pharmaceutical companies, medical device manufacturers and health care providers to ensure they have internal processes that adequately anticipate and meet the baseline requirements.

Read the full article here. | Source:

Last Updated on Wednesday, 03 August 2011 13:36